Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
Study Details
Study Description
Brief Summary
The purpose of this study is to estimate the relative bioavailability (rBA) of nirmatrelvir/ritonavir oral powder in 3 different food vehicles relative to the Paxlovid® tablets under fasted condition in healthy adult participants, and to estimate the effect of food on the rBA of the nirmatrelvir/ritonavir oral powder formulation. The study will also assess the safety, tolerability, and palatability of nirmatrelvir/ritonavir oral powder in healthy adult participants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Treatment A: Nirmatrelvir/ritonavir Nirmatrelvir and ritonavir tablets |
Drug: Nirmatrelvir/ ritonavir
Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
|
| Experimental: Treatment B: Nirmatrelvir/ ritonavir Nirmatrelvir/ritonavir with water |
Drug: Nirmatrelvir/Ritonavir
Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition
|
| Experimental: Treatment C: Nirmatrelvir/ ritonavir Nirmatrelvir/ ritonavir with infant formula |
Drug: Nirmatrelvir/Ritonavir
Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
|
| Experimental: Treatment D: Nirmatrelvir/ ritonavir Nirmatrelvir/ ritonavir with vanilla pudding |
Drug: Nirmatrelvir/ritonavir
Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
|
| Experimental: Treatment E: Nirmatrelvir/ ritonavir Nirmatrelvir/ ritonavir with food and vanilla pudding |
Drug: Nirmatrelvir/ritonavir
Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
|
Outcome Measures
Primary Outcome Measures
- Area under curve from time zero to 72 hours post dose [0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours]
- Peak plasma concentration (Cmax) [0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours]
Secondary Outcome Measures
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) [Baseline (Day 0) up to 28 days after last dose of study medication]
- Number of Participants With Notable Electrocardiogram (ECG) Values [Baseline (Day 0) up to day 4 of treatment period 5]
- Number of Participants With Clinically Notable Vital Signs [Baseline (Day 0) up to day 4 of treatment period 5]
- Number of Participants With Clinically Notable Changes in Clinical laboratory [Baseline (Day 0) up to day 4 of treatment period 5]
- Number of Participants With Clinically Notable Abnormality in physical examination [Baseline (Day 0) up to day 4 of treatment period 5]
- Palatability assessment of nirmatrelvir/ritonavir oral powder mixed with water/infant formula/vanilla pudding [1, 5, 10 and 20 minutes]
- Area under curve from time zero to 72 hours post dose [0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours]
- Peak plasma concentration (Cmax) [0 , 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 48 and 72 hours]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination (PE), laboratory tests, vital signs and standard 12 lead ECGs.
-
Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
-
Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
Exclusion Criteria:
-
Positive test result for SARS-CoV-2 infection at the time of Screening or Day -1.
-
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
-
Clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, unstable ischemic conditions, evidence of ventricular dysfunction, serious tachy or brady arrhythmias) or indicating serious underlying heart disease (eg, prolonged PR interval, cardiomyopathy, heart failure greater than New York Heart Association (NYHA) 1, underlying structural heart disease, Wolff Parkinson-White syndrome).
-
Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
-
History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis B surface antibody (HCVAb). Hepatitis B vaccination is allowed.
-
Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
-
Participant who have received a COVID-19 vaccine within 7 days before screening or admission, or who are to be vaccinated with a COVID-19 vaccine at any time during the study confinement period.
-
A positive urine drug test.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- C4671036
- 2022-002497-86